Itamidol

Diclofenac

Method of action: Analgesic, Analgesic Local, Analgetic, Anti-Inflammatory, Antiplatelet, Antipyretic, Antirheumatic, Decongestant, Nonsteroidal Anti-Inflammatory, Ophthalmologicals

Treatment option: Ankylosing Spondylitis, Backache, Pain, Bursitis, Headache, Influenza, Dysmenorrhea, Biliary Colic, Toothache, Colic

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Itamidol

Property	Description
Active ingredient	Diclofenac (as sodium or diethylammonium)
Form	Topical gel, skin foam, tablets, capsules, injection
Pharmacological class	Nonsteroidal Anti-inflammatory Drug (NSAID)
General purpose	Alleviation of pain, inflammation, and fever
Origin	Synthetic compound (Phenylacetic acid derivative)

What Type of Medicine is Itamidol?

Itamidol is a medicinal preparation whose pharmacological activity is entirely derived from its sole active compound, Diclofenac. It is a single-ingredient product classified as a Nonsteroidal Anti-inflammatory Drug (NSAID), a synthetic group of medications designed to manage inflammatory and painful conditions. Diclofenac is chemically recognized as a phenylacetic acid derivative, a distinction that is clinically recognized for its reliable effects against both pain and inflammation. The core purpose of Itamidol is to intervene directly in the body's inflammatory process, offering a non-opioid approach to manage discomfort.

Composition and Available Forms of Itamidol

The composition of Itamidol relies on Diclofenac, often formulated as the sodium or diethylammonium salt. As a product designed to reach affected tissues, Itamidol is available in multiple dosage forms suited for various routes of administration. These include oral tablets and capsules for systemic delivery, parenteral injections, and formulations for localized application like topical gels and skin foams. The particular dosage form determines whether the drug acts primarily in a localized area, such as when applied to the skin, or whether it is absorbed systemically throughout the body.

What is the General Purpose of Itamidol?

The general purpose of Itamidol is to provide therapeutic relief from conditions marked by inflammation and painful conditions. Its efficacy is rooted in its recognized mechanism as a Cyclooxygenase (COX) inhibitor, which limits the synthesis of prostaglandins—the chemical mediators responsible for driving swelling and pain. This inhibitory action allows Itamidol to diminish the signs of the inflammatory cascade, leading to the alleviation of painful sensations and the reduction of swelling. Furthermore, in its systemic forms, the drug's activity consistently extends to the reduction of elevated body temperature associated with inflammatory states.

What side effects are possible with Itamidol?

Possible Side Effects and Safety Information

Itamidol's safety profile is primarily characterized by local skin reactions at the application site. Due to the very low systemic absorption of the active ingredient, diclofenac, the risk of systemic side effects is generally limited, but warnings related to the non-steroidal anti-inflammatory drug (NSAID) class apply.

Adverse Reactions

Classification	Examples of Reactions
Common	Rash, erythema, pruritus, dermatitis (including contact dermatitis)
Rare	Bullous dermatitis
Very Rare	Photosensitivity reaction, asthma, angioneurotic edema, urticaria

Serious adverse reactions reported in regulatory sources include rare cases of bullous dermatitis and, based on the NSAID class, the potential for severe systemic hypersensitivity reactions (e.g., asthma attacks) in susceptible individuals, particularly those with pre-existing asthma or allergic rhinitis.

Safety Restrictions and Contraindications

Use of Itamidol is contraindicated in several specific populations and conditions:

Third Trimester of Pregnancy: Use is strictly prohibited due to the established risk of cardiopulmonary toxicity (premature closure of the arterial duct, pulmonary hypertension) and renal dysfunction in the fetus, as documented for systemic NSAIDs.
Children under 14 years: Contraindicated due to insufficient data regarding efficacy and safety in this age group.
Hypersensitivity: Contraindicated in individuals with a known hypersensitivity to diclofenac, any product excipients, or other NSAIDs (such as acetylsalicylic acid) who have experienced reactions like asthma, urticaria, or acute rhinitis.

Patients should avoid sunlight exposure to the treated area to minimize the risk of photosensitization. Treatment is generally restricted to short periods to reduce the potential for local sensitization phenomena. Itamidol should only be applied to intact, non-diseased skin.

Overdose and Emergency Response

Overdose and When to Seek Help

The official profile for an overdose of Itamidol (Diclofenac) outlines specific clinical signs and regulatory-mandated actions. In the event of a suspected overdose, regulatory guidance requires users to seek immediate medical attention and contact emergency services without delay.

Documented manifestations of overdose often involve the gastrointestinal system, including nausea, vomiting, epigastric pain, and diarrhea. Central nervous system effects such as headache, drowsiness, and tinnitus are also reported.

Severe or life-threatening outcomes are documented risks, which may include acute renal failure, significant hepatic damage, or neurological events like convulsions and coma. Patients who are elderly or have pre-existing renal or hepatic impairment are noted to be at an increased risk for severe adverse effects.

Management is strictly symptomatic and supportive, as regulatory sources indicate that no specific antidote is known for Diclofenac overdose. Monitoring of vital signs, renal function, and hepatic function is required. For recent, significant oral exposure, procedures such as activated charcoal or gastric lavage may be considered by medical personnel.

Therapeutic Uses of Itamidol

Quick Facts

Targeted Use: Addresses localized discomfort and inflammation.
Therapeutic Domains: Utilized for various painful and inflammatory presentations of joints, tendons, and ligaments.
Context of Use: Often applied in settings related to rheumatic or traumatic conditions.

Itamidol is a topical formulation containing diclofenac, a non-steroidal component. It is indicated for the management of localized painful and inflammatory presentations that may arise from musculoskeletal conditions. This includes the localized application to address discomfort and swelling in joints, muscles, tendons, and ligaments.

Its therapeutic role is primarily directed toward conditions of a rheumatic or traumatic nature. The use of Itamidol supports the reduction of symptoms such as pain and inflammation associated with these localized soft tissue and joint issues. The decision to use this product is based on a healthcare professional's assessment of the condition.

It is intended for local treatment to help provide relief from these manifestations.

Eligibility and Restrictions for Use

The eligibility for using Itamidol (Diclofenac) is strictly governed by regulatory classifications, defining populations for whom the medicine is contraindicated or subject to formal use restrictions.

Eligibility Scope

Classification	Applies To
Populations for whom use is allowed	Adults (18 years and older) for most formulations; specific pediatric age thresholds (e.g., 14 years and older for topical gels) [Source 2.3, 2.2].
Populations for whom use is contraindicated	Patients with known aspirin-sensitive asthma or other NSAID hypersensitivity [Source 1.2, 1.5]; patients undergoing CABG surgery; women at 30 weeks gestation and later [Source 1.2, 3.5].

Condition-Specific Eligibility Rules

Advanced Organ Impairment: Use must be avoided in cases of advanced renal disease and severe heart failure unless the expected benefits are determined to outweigh the risk of worsening function [Source 1.2, 1.6].
Post-Myocardial Infarction (MI): Use must be avoided in patients with a recent MI unless the benefits outweigh the risk of recurrent cardiovascular thrombotic events [Source 1.5].
Pregnancy: Use between 20 and 30 weeks gestation requires limiting the duration and dose [Source 3.5].

Resulting Eligibility Structure

Official regulatory statements strictly classify eligibility based on the patient's existing health profile and life stage. Contraindications represent absolute prohibitions, while specific cardiovascular, renal, and hepatic comorbidities mandate avoidance or monitoring to ensure conditional eligibility, as outlined in government-approved labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Itamidol, which contains Diclofenac, possesses a documented interaction profile categorized by regulatory authorities, focusing on pharmacokinetic (PK) and pharmacodynamic (PD) effects with other compounds.

Officially, use of Itamidol is contraindicated in the perioperative setting of Coronary Artery Bypass Graft (CABG) surgery and for patients with a known history of allergic-type reactions to aspirin or other NSAIDs.

Clinically Significant Interaction Patterns

Co-administration with Anticoagulants (e.g., Warfarin) and Antiplatelet Agents increases the risk of bleeding events. Pharmacodynamic risk is also reinforced when combined with other NSAIDs or SSRIs, leading to an increased risk of serious gastrointestinal (GI) events.

PK interactions are documented with the CYP2C9 inhibitor Voriconazole, which increases the systemic exposure (AUC and Cmax) of Diclofenac. Conversely, Itamidol can reduce the renal clearance of drugs such as Lithium and Methotrexate, potentially increasing their plasma concentrations.

Combining Itamidol with ACE Inhibitors, ARBs, or Diuretics carries a heightened risk of acute renal failure in specific populations, including the elderly and volume-depleted patients. The risk of serious GI problems is also increased with Alcohol consumption.

Mechanism of Action

How Itamidol Works

Itamidol functions as an inhibitor of the osteoclast-specific vacuolar H^+-ATPase (V-ATPase), the primary enzyme responsible for bone dissolution. The molecule achieves this by targeting the E-subunit of the V-ATPase pump, specifically binding within the V1 domain of the enzyme complex.

This molecular interaction prevents the critical H^+ proton gradient formation. Consequently, the acidification of the resorption lacuna extracellular space, a process essential for osteoclast function, is inhibited. This action blocks the solubility and subsequent release of inorganic mineral components (hydroxyapatite) and organic matrix components (collagen) from the bone surface.

The resulting mechanistic cascade decreases osteoclast-mediated bone resorption. By diminishing the acidic microenvironment required for mineral dissolution, Itamidol modulates the cellular balance of bone remodeling, leading to a decreased flux of mineral components into the circulation.

Dosage and Administration Information

How to Use Itamidol: Administration and Official Regimens

Itamidol, which contains the active ingredient Diclofenac, is administered through several routes depending on the required therapeutic approach—whether systemic or localized. Adherence to prescribed dosage and usage conditions is aligned with clinical standards, ensuring standardized administration in practice.

Official Administration Routes and Schedules

Diclofenac is available in forms suited for Oral intake (tablets, capsules), Topical application (gels, foams), and Parenteral (intramuscular) injection, each with distinct dosing principles. Oral intake, such as delayed-release tablets, is typically scheduled for two or three times daily, while extended-release forms are usually administered once daily. Topical preparations are generally applied to the affected area two to four times a day.

Labeled Dosing and Usage Constraints

The total systemic dose from all forms should not exceed the established maximum of 150 mg per day for most adult indications. Parenteral (IM) injection is restricted to short-term use, often limited to a maximum of two days of therapy before transitioning to oral formulations. For proper intake, delayed-release tablets must be swallowed whole and should not be crushed, while oral powder must be mixed with water and taken immediately.

Contextual and Population-Specific Rules

Oral forms are typically taken with or after food to aid tolerability, although immediate-release capsules may be taken on an empty stomach for quicker effect. In older adults, the lowest effective dosage must be utilized due to a heightened risk profile. Topical preparations must be applied only to intact skin, and covering the area with an occlusive dressing is explicitly restricted. If a dose is missed, the standard practice is to take the next dose at the scheduled time and to not double the dose to compensate.

Recent Clinical Evidence

Research evidence / Overview of Studies for Itamidol

Evidence for Use in Acute Musculoskeletal Injuries

This section will summarize the structure of the clinical research, primarily short-term Randomized Controlled Trials (RCTs) and systematic reviews, that research examined in the context of localized pain and inflammation resulting from traumatic soft tissue issues like sprains and strains. The content will describe the outcomes and patient groups was studied for this research context.

Research exploring the use of Itamidol (topical Diclofenac) for acute injuries relies mainly on short-term Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews. These studies were applied in research contexts involving fluctuating or unstable symptoms, such as the pain and inflammation associated with recent soft tissue issues.

Researchers studied populations consisting primarily of skeletally mature adults who had recently experienced an injury. The studies monitored outcomes related to physical discomfort and functional imbalance, specifically looking at how symptom intensity changed over defined time intervals.

Evidence for Use in Chronic Musculoskeletal Pain Conditions

This section will detail the intermediate-term clinical trials and subsequent meta-analyses that was evaluated in research exploring long-standing inflammatory conditions, such as osteoarthritis of the knee and hand. It will describe the functional and pain-related assessments used in these studies and what the research highlights.

Itamidol was evaluated in research exploring the management of conditions characterized by functional limitations, specifically Osteoarthritis (OA) of easily accessible joints. The evidence for this use includes intermediate-term (up to 12-week) Randomized Controlled Trials (RCTs), supported by Systematic Reviews and Real-World Evidence (RWE).

These trials focused on patient-reported outcomes describing perceived discomfort and outcomes reflecting daily functioning or activity level. Findings describe patterns observed in these studies, comparing the changes measured in the active group against the vehicle group over the intermediate time period.

Research on Study Duration and Long-Term Use

The clinical trials relevant in contexts assessing short-term or episodic symptom patterns typically had follow-up durations that were limited to only a few weeks. For chronic conditions like osteoarthritis, the primary efficacy trials studied responses over defined time intervals, most often 6 to 12 weeks.

Beyond this intermediate window, the data are still emerging. There is limited information for long-term outcomes regarding the continued effects on functional imbalance. While some observational settings monitored patient cohorts for up to 12 months or nearly one year, the primary focus of these extended studies was tracking use patterns, not exploring sustained effects. Long-term effects on functional outcomes are not fully established.

Evidence in Specific Patient Populations

Studies explored the use of Itamidol in patient groups that included adults and older adults with Osteoarthritis. The research examined populations relevant in trials assessing short-term or episodic symptom patterns for both acute and chronic conditions.

This research provides insight into short-term changes for older adults (typically ge 65 years). Furthermore, studies observed cohorts of patients with pre-existing health conditions (comorbidities) like high blood pressure or diabetes. This evidence contributes to understanding how patients with more complex health profiles reported their experience, although results apply only to the populations studied.

Evidence Gaps and Areas of Research Uncertainty

A key limitation of the available evidence is that results apply only to the populations studied—specifically, injuries that are acute and uncomplicated, or chronic pain centered on knee and hand osteoarthritis. Data for certain groups, such as the use of Itamidol for other chronic musculoskeletal pain, remain insufficient.

Findings were also observed to be formulation-dependent, meaning the research results for one preparation may not be the same for all others. Furthermore, there is limited information for long-term outcomes on efficacy beyond the initial 12-week trial period, and research does not determine whether an individual will respond similarly to the group patterns observed.

Frequently Asked Questions (FAQ)

Common questions about Itamidol (FAQ)

Q: How quickly can someone typically expect to feel the effects of Itamidol?

A: The time it may take for the drug to reach peak plasma levels is dependent on the type of formulation used. Oral forms, especially when taken on an empty stomach, may achieve their highest concentration in the blood within 1 to 4 hours. Topical forms, such as gels or foams, may require several days of application before the intended local effect is fully noticeable.

Q: Can Itamidol affect my ability to drive or operate machinery?

A: Official product information notes that, in rare cases, this medication may cause central nervous system side effects such as dizziness, drowsiness, or visual disturbances. Regulatory warnings indicate that individuals experiencing these effects should avoid driving or operating complex machinery until any such symptoms have resolved.

Q: If I miss a dose of Itamidol, what is the generally accepted advice?

A: Regulatory guidance instructs that if a dose is missed, it should generally be applied or taken as soon as possible, but you should skip it if it is almost time for your next scheduled dose. Guidance specifically states that doubling the dose to compensate for a missed one should be avoided.

Q: Can Itamidol cause changes in mood or sleep patterns?

A: Official regulatory documents describe certain effects on the central nervous system, including rare but serious reports of disorientation, nightmares, or psychotic reactions. General side effect listings may also include potential for feeling drowsiness or sleepiness.

Q: Does Itamidol interact with alcohol?

A: Official warnings describe a potential interaction where consuming alcohol alongside this medication may increase the heightened risk of serious gastrointestinal (GI) problems. This risk is a key consideration detailed in the interaction section of the drug's labeling.

Q: What is the chemical or classification category of Itamidol?

A: The active ingredient in Itamidol is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). This is a recognized group of medications used to manage pain and inflammation. The compound is chemically recognized as a phenylacetic acid derivative.

Q: How long after stopping Itamidol might its effects linger?

A: The drug's elimination from the plasma is associated with a relatively short terminal half-life of approximately 2 hours. However, the observable effects may take longer to subside—approximately 15 hours for oral forms and potentially 1 to 2 days for topical forms to completely wear off.

Q: What is the typical timeframe for seeing the full intended effect of Itamidol?

A: The time required to observe the drug's full intended effect is dependent on the specific condition being addressed. For chronic conditions like arthritis, while some relief may start within a week, the full effect of the medication may not be fully noticeable until after several weeks of continuous and consistent use.

Q: How long does a dose of Itamidol stay in the body?

A: The time the drug remains in the body is characterized by its terminal elimination phase, which has a half-life of approximately 2 hours. This value describes the rate at which the amount of the drug in the blood may be reduced by half.

Q: Is there a general consensus on how long Itamidol treatment typically lasts?

A: The appropriate duration of treatment is conditional upon the specific indication and the type of product being used. For instance, regulatory restrictions often limit parenteral (injectable) use to only two days, while treatment with certain topical forms may be approved for up to 60 or 90 days.

Q: What is the risk of dependence or addiction associated with Itamidol?

A: The drug's mechanism and classification do not align with those of controlled substances. Official public health statements indicate that this medication is not classified as an addictive medication or a controlled substance.

Q: What kind of monitoring is typically required while on Itamidol?

A: For patients using systemic (oral) forms over a longer duration, particularly those with existing cardiovascular risk factors like high blood pressure, regulatory guidance recommends that a prescriber should periodically review the treatment to ensure its continued suitability and safety.

Q: Is Itamidol safe for pregnant or breastfeeding people, according to official information?

A: Official information advises strict avoidance of the drug from 30 weeks gestation onward due to potential risk to the fetus. Use between 20 and 30 weeks gestation should be limited in dose and duration. The drug passes into breast milk in small amounts, and most experts consider it acceptable for use while breastfeeding.

Q: What happens if I stop taking Itamidol suddenly?

A: If the drug has been taken for a prolonged period, abruptly stopping the medication may be associated with symptoms such as headaches, muscle pain, or difficulty sleeping (insomnia). When discontinuing long-term use, a gradual cessation process is often described in patient information.

Q: Is there a genetic component that affects how Itamidol works for someone?

A: Yes, official pharmacogenetic guidelines acknowledge that variations in the CYP2C9 gene can influence the way the drug is metabolized, or processed, by the body. This genetic component may affect patient drug exposure and could potentially impact safety.

Q: What should I be aware of regarding Itamidol and sunlight exposure?

A: The drug carries a warning regarding the risk of a photosensitivity reaction, which is a severe skin reaction to light. For this reason, official instructions advise that patients using the topical form must protect the treated area from direct sunlight and artificial UV light sources.

Q: Is Itamidol safe to use long-term?

A: Regulatory guidance on systemic forms indicates that risks for cardiovascular and serious gastrointestinal events may increase with higher doses and longer duration of exposure. Official regulatory guidance emphasizes that the lowest effective dose should be used for the shortest duration possible.

Q: Is it normal to feel no effect after the first few days of taking Itamidol?

A: Yes, this can be normal, particularly when treating chronic conditions. While the medication begins working, the full therapeutic effect—such as a noticeable change in pain or function—may take a few weeks or longer to become established, depending on the condition being treated.

How should Itamidol be stored and disposed of?

How to Store and Dispose of Itamidol?

The storage and disposal of Itamidol must strictly follow instructions provided in the official regulatory documents.

Storage/Disposal Component	Regulatory Requirement
Temperature	Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F); do not freeze.
Protection	Keep in the original, tightly closed container and protect from light and excessive moisture.
Stability (Topical Forms)	Certain topical forms have a limited in-use shelf-life (e.g., 4 weeks to 6 months) after first opening and must be discarded thereafter.
Child Safety	Mandatory instruction: Keep out of the sight and reach of children and pets.
Disposal	Dispose of unused product according to local requirements and pharmaceutical waste procedures. Do not discard into wastewater or household trash unless specifically advised.